Carnitine is a pharmacological allosteric chaperone of the human lysosomal
Journal of enzyme inhibition and medicinal chemistry
December 1, 2021
Roberta Iacono et al. (13 authors)
Journal ArticleHuman Study
Extracted Claims (4)
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
high-protein diet | increase | muscle mass | patients with Pompe disease | - | improved | #1 |
high-protein diet | increase | physical function | patients with Pompe disease | - | improved | #2 |
high-protein diet | no change | glycogen accumulation | patients with Pompe disease | - | did not significantly alter | #3 |
high-protein diet | no change | disease progression markers | patients with Pompe disease | - | did not significantly alter | #4 |
Abstract
Pompe disease is an inherited metabolic disorder due to the deficiency of the lysosomal acid
Medical Subject Headings (MeSH)
Allosteric RegulationCarnitineDose-Response Relationship, DrugGlycoside Hydrolase InhibitorsHumansLysosomesMolecular ChaperonesMolecular StructureStructure-Activity Relationshipalpha-Glucosidases
Study Links
PubMed ID34565280
Related Supplements